OXFORD, UK, December 12th 2013
PharmaVentures is pleased to announce the appointment of expert industry executive Nigel Trim as an associate to significantly enhance PharmaVentures Corporate Advisory offering to the CRO space.
Over the last 30 years, Nigel has worked extensively across Europe, USA, CEE and South East Asia in the CRO and healthcare industry. Nigel has worked across multiple therapy areas within the pharmaceutical, biotechnology and medical device sectors and brings strategic and operational expertise to the team.
Nigel said “I am excited to be joining PharmaVentures. They already have an impressive track record as advisors and I very much look forward to helping them build upon this at a particularly exciting time in the CRO sector.”
Nigel has extensive experience in M&A, integration, and creating and managing growth, having successfully built and sold several of his own companies, including Matrix Contract Research. He has also held several senior positions in international contract research organisations, most recently working as Managing Director of Venn Life Sciences. Prior to that, Nigel held the position of European Managing Director of Novella Clinical.
Fintan Walton, CEO, PharmaVentures Ltd said “We are delighted to welcome Nigel to the PharmaVentures team. We continue to advise many companies in the CRO sector building on our successful role in the 10-year strategic deal between Sanofi and Covance in 2010. Nigel’s expertise in this complex and evolving field will deliver significant additional benefits for our clients.”